MX2016005506A - Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas. - Google Patents

Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.

Info

Publication number
MX2016005506A
MX2016005506A MX2016005506A MX2016005506A MX2016005506A MX 2016005506 A MX2016005506 A MX 2016005506A MX 2016005506 A MX2016005506 A MX 2016005506A MX 2016005506 A MX2016005506 A MX 2016005506A MX 2016005506 A MX2016005506 A MX 2016005506A
Authority
MX
Mexico
Prior art keywords
cytidine
modified nucleotide
methods related
nucleotide compositions
carboxamide modified
Prior art date
Application number
MX2016005506A
Other languages
English (en)
Other versions
MX371440B (es
Inventor
Nathu Gawande Bharat
Janjic Nebojsa
Rohloff John
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of MX2016005506A publication Critical patent/MX2016005506A/es
Publication of MX371440B publication Critical patent/MX371440B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/117—Modifications characterised by incorporating modified base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen en el presente documento 5 posiciones de nucleótidos de citosina y nucleósidos modificados, así como fosforamiditas y trifosfatos derivados de los mismos. Además se proporcionan métodos de fabricación y uso de la misma, y composiciones y usos de los nucleósidos modificados, como parte de una molécula de ácido nucleico (por ejemplo, aptámero).
MX2016005506A 2013-11-21 2014-11-19 Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas. MX371440B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907274P 2013-11-21 2013-11-21
PCT/US2014/066328 WO2015077292A1 (en) 2013-11-21 2014-11-19 Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Publications (2)

Publication Number Publication Date
MX2016005506A true MX2016005506A (es) 2016-08-03
MX371440B MX371440B (es) 2020-01-30

Family

ID=53180088

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005506A MX371440B (es) 2013-11-21 2014-11-19 Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.
MX2020001158A MX2020001158A (es) 2013-11-21 2016-04-27 Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001158A MX2020001158A (es) 2013-11-21 2016-04-27 Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.

Country Status (15)

Country Link
US (2) US9938314B2 (es)
EP (2) EP3071588A4 (es)
JP (3) JP7008405B2 (es)
KR (1) KR102290214B1 (es)
CN (1) CN105658658B (es)
AU (1) AU2014353102B2 (es)
BR (1) BR112016010165A2 (es)
CA (1) CA2928207C (es)
HK (2) HK1223625A1 (es)
IL (3) IL244641A0 (es)
MX (2) MX371440B (es)
RU (1) RU2732402C2 (es)
SG (1) SG10202006426QA (es)
TW (1) TWI632155B (es)
WO (1) WO2015077292A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
BR112012025872B8 (pt) * 2010-04-12 2021-05-25 Somalogic Inc primidinas modificadas na posição-5
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
SG10202006426QA (en) * 2013-11-21 2020-08-28 Somalogic Inc Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
ES2764669T3 (es) 2014-02-18 2020-06-04 Somalogic Inc Composiciones y métodos para la detección de microorganismos
AU2017218889A1 (en) 2016-02-09 2018-08-30 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
EP3913058B1 (en) 2016-07-01 2025-01-01 SomaLogic Operating Co., Inc. Oligonucleotides comprising modified nucleosides
CN107663220B (zh) * 2016-07-27 2020-10-02 上海伯豪医学检验所有限公司 修饰碱基、包含修饰碱基的核酸、适配体及其应用
EP3548652B1 (en) 2016-12-01 2024-04-03 Nautilus Subsidiary, Inc. Methods of assaying proteins
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
LT6615B (lt) 2017-09-12 2019-04-25 Vilniaus Universitetas N4-modifikuoti citidino nukleotidai ir jų panaudojimas
CA3086915A1 (en) 2017-12-29 2019-07-04 Sujal M. Patel Decoding approaches for protein identification
IL291839A (en) 2019-10-01 2022-06-01 Empyrean Neuroscience Inc Genetic engineering of fungi to modulate tryptamine expression
EP4165549A1 (en) 2020-06-11 2023-04-19 Nautilus Biotechnology, Inc. Methods and systems for computational decoding of biological, chemical, and physical entities
CA3203106A1 (en) 2021-01-20 2022-07-28 Parag Mallick Systems and methods for biomolecule quantitation
WO2022159663A1 (en) 2021-01-21 2022-07-28 Nautilus Biotechnology, Inc. Systems and methods for biomolecule preparation
IL305336B2 (en) 2021-03-11 2025-09-01 Nautilus Subsidiary Inc Systems and methods for preserving biomolecules
EP4399528A1 (en) 2021-09-09 2024-07-17 Nautilus Subsidiary, Inc. Characterization and localization of protein modifications
US20230090454A1 (en) 2021-09-22 2023-03-23 Nautilus Biotechnology, Inc. Methods and systems for determining polypeptide interactions
US20230149883A1 (en) 2021-11-03 2023-05-18 Nautilus Biotechnology, Inc. Systems and methods for surface structuring
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
CN114524855A (zh) * 2022-02-22 2022-05-24 武汉大学 一种5-醛基胞嘧啶亚磷酰胺单体的合成方法
WO2023192917A1 (en) 2022-03-29 2023-10-05 Nautilus Subsidiary, Inc. Integrated arrays for single-analyte processes
WO2023212490A1 (en) 2022-04-25 2023-11-02 Nautilus Subsidiary, Inc. Systems and methods for assessing and improving the quality of multiplex molecular assays
EP4544077A1 (en) 2022-06-21 2025-04-30 Nautilus Subsidiary, Inc. Method for detecting analytes at sites of optically non-resolvable distances
US20240094215A1 (en) 2022-09-15 2024-03-21 Nautilus Subsidiary, Inc. Characterizing accessibility of macromolecule structures
WO2024073599A1 (en) 2022-09-29 2024-04-04 Nautilus Subsidiary, Inc. Preparation of array surfaces for single-analyte processes
EP4619766A1 (en) 2022-11-15 2025-09-24 Nautilus Subsidiary, Inc. Standard polypeptides
EP4630816A1 (en) 2022-12-09 2025-10-15 Nautilus Subsidiary, Inc. A method comprising performing on a single-analyte array at least 50 cycles of a process
US20240201182A1 (en) 2022-12-15 2024-06-20 Nautilus Subsidiary, Inc. Inhibition of photon phenomena on single molecule arrays
US20240241110A1 (en) 2023-01-12 2024-07-18 Nautilus Subsidiary, Inc. Characterization of glycans and glycoconjugates
WO2024206122A1 (en) 2023-03-24 2024-10-03 Nautilus Subsidiary, Inc. Improved transfer of nanoparticles to array surfaces
WO2024216233A1 (en) 2023-04-13 2024-10-17 Nautilus Subsidiary, Inc. Artificial proteins for displaying epitopes
WO2024243237A1 (en) 2023-05-24 2024-11-28 Nautilus Subsidiary, Inc. Systems and methods for machine vision
US20250189519A1 (en) 2023-12-11 2025-06-12 Nautilus Subsidiary, Inc. Methods and compositions of particle-based arrays
WO2025137166A1 (en) 2023-12-20 2025-06-26 Nautilus Subsidiary, Inc. Fluidic devices for single-analyte assays
US20250298016A1 (en) 2024-03-22 2025-09-25 Nautilus Subsidiary, Inc. Plasmonic particle systems for single-analyte assays
WO2025212338A1 (en) 2024-04-01 2025-10-09 Nautilus Subsidiary, Inc. Nanostructures for modulation of analyte conformation
WO2026003215A1 (fr) * 2024-06-27 2026-01-02 Commissariat A L'energie Atomique Et Aux Energies Alternatives Bases modifiées chimiquement avec un groupement clivable et méthodes de sélection d'acides nucléiques fonctionnels les comprenant

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4594339A (en) 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US5047519A (en) 1986-07-02 1991-09-10 E. I. Du Pont De Nemours And Company Alkynylamino-nucleotides
US4997818A (en) 1987-09-21 1991-03-05 The University Hospital Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
CA2058632C (en) 1989-06-05 2004-08-24 Brian C. Froehler Exonuclease-resistant oligonucleotides and methods for preparing the same
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
AU7473791A (en) 1990-03-13 1991-10-10 Acic (Canada) Inc. Process for producing 2,2'-o-cyclonucleosides, nucleosides, and analogs thereof
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
RU2088588C1 (ru) * 1990-07-02 1997-08-27 Хехст АГ Олигонуклеотиды и способ их получения
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5719273A (en) 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
AU727460B2 (en) 1995-05-03 2000-12-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
JP4899014B2 (ja) * 1995-06-02 2012-03-21 イーシー・テクノロジー・エルエルシー 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法
AU721747B2 (en) * 1995-06-02 2000-07-13 Ec Technology, Llc Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
JP3485023B2 (ja) 1999-05-20 2004-01-13 東亞合成株式会社 ヌクレオシド化合物
ES2319732T3 (es) 2000-04-13 2009-05-12 Pharmasset, Inc. Derivados de nucleosido 3'- o 2'-hidroximetilo sustituido para el tratamiento de infecciones virales.
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1481090A4 (en) 2002-02-15 2006-08-09 Somalogic Inc METHOD AND REAGENTS FOR DETECTING BINDING OF TARGET MOLECULES BY NUCLEIC ACID ELECTRODES
JP3978187B2 (ja) 2002-03-19 2007-09-19 富士通株式会社 機能性分子及びその製造方法
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
JP4119976B2 (ja) 2003-02-07 2008-07-16 国立大学法人群馬大学 ５位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法
US20050227225A1 (en) 2004-04-07 2005-10-13 Roche Molecular Systems, Inc. Stabilization of biomolecules in samples
EP3034510A1 (en) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
US20060142311A1 (en) 2004-11-18 2006-06-29 Kyoto University Prodan-containing nucleotide and use thereof
JP4596902B2 (ja) 2004-12-10 2010-12-15 株式会社日立製作所 ストレージ管理装置、計算機システム、ストレージ管理方法及びストレージ管理プログラム
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
EP2952894B1 (en) 2006-01-17 2017-08-30 Somalogic, Inc. Kits comprising aptamers
US8242258B2 (en) 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
WO2008078180A2 (en) 2006-12-22 2008-07-03 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
WO2008104408A2 (en) 2007-02-27 2008-09-04 K. U. Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
WO2008137776A2 (en) 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
MX344253B (es) 2007-07-17 2016-12-09 Somalogic Inc Metodo para generar aptameros con constantes de disociacion mejoradas.
US8404830B2 (en) 2007-07-17 2013-03-26 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20090215050A1 (en) 2008-02-22 2009-08-27 Robert Delmar Jenison Systems and methods for point-of-care amplification and detection of polynucleotides
US8703416B2 (en) * 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
US8569252B2 (en) 2009-04-15 2013-10-29 Postech Academy-Industry Foundation Nucleolin specific aptamer and use thereof
WO2011032143A2 (en) 2009-09-14 2011-03-17 Paul Dimaggio Submersible hydroelectric power generator and methods thereof
AU2011223527B2 (en) 2010-03-03 2014-11-13 Somalogic Operating Co., Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
WO2011130065A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF MET GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
BR112012025872B8 (pt) * 2010-04-12 2021-05-25 Somalogic Inc primidinas modificadas na posição-5
CA2817002C (en) 2010-11-05 2019-01-15 Miragen Therapeutics Base modified oligonucleotides
WO2012174496A2 (en) * 2011-06-17 2012-12-20 Somalogic, Inc. Method for purification and identification of sperm cells
SG10202006426QA (en) * 2013-11-21 2020-08-28 Somalogic Inc Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Also Published As

Publication number Publication date
IL263380B (en) 2019-11-28
IL263380A (en) 2018-12-31
SG10202006426QA (en) 2020-08-28
US10239908B2 (en) 2019-03-26
US20180201641A1 (en) 2018-07-19
KR20160078989A (ko) 2016-07-05
JP7008405B2 (ja) 2022-01-25
EP3071588A4 (en) 2017-08-02
IL269461A (en) 2019-11-28
BR112016010165A2 (pt) 2017-12-05
TW201542580A (zh) 2015-11-16
HK1223625A1 (zh) 2017-08-04
JP2016540755A (ja) 2016-12-28
CN105658658B (zh) 2019-11-05
IL269461B (en) 2020-05-31
US9938314B2 (en) 2018-04-10
WO2015077292A1 (en) 2015-05-28
AU2014353102A1 (en) 2016-03-31
KR102290214B1 (ko) 2021-08-18
AU2014353102B2 (en) 2019-05-16
EP3330277A2 (en) 2018-06-06
HK1252242A1 (en) 2019-05-24
IL244641A0 (en) 2016-04-21
CA2928207C (en) 2020-09-15
TWI632155B (zh) 2018-08-11
CA2928207A1 (en) 2015-05-28
EP3330277A3 (en) 2018-09-26
JP2021073211A (ja) 2021-05-13
RU2732402C2 (ru) 2020-09-16
EP3071588A1 (en) 2016-09-28
JP2020090534A (ja) 2020-06-11
MX2020001158A (es) 2020-03-12
CN105658658A (zh) 2016-06-08
RU2016124202A (ru) 2017-12-26
US20160215013A1 (en) 2016-07-28
MX371440B (es) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2020001158A (es) Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas.
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2012011779A (es) Pirimidinas modificadas en la posicion 5 y su uso.
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
EP2791160A4 (en) NUCLEOSIDE, NUCLEOTIDE, AND MODIFIED NUCLEIC ACID COMPOSITIONS
PH12014502094B1 (en) Substituted nucleosides, nucleotides and analogs thereof
HK1224229A1 (zh) 取代的核苷，核苷酸及其类似物
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
HK1213018A1 (zh) 橋接雙環核苷
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
NZ631071A (en) Methods and compositions for modulating apolipoprotein(a) expression
IL232843A0 (en) 4'-azido', 3'-fluoro modified nucleoside derivatives as inhibitors of hepatitis C virus RNA replication
WO2014210199A3 (en) Methods of performing polymerase chain reaction and related uses thereof
BR112018017316A2 (pt) compostos e métodos para a síntese de 5-(n-protegido-triptaminocarboxiamida)-2?-desoxiuridina fosforamidato para incorporação em uma sequência nucleica
TH1401003558A (th) อนุพันธ์นิวคลีโอไซด์ที่ถูกแทนที่แบบ 4'-อะซิโด,3'-ฟลูออโรในฐานะที่เป็นตัวยับยั้งการถ่ายแบบ rna ของ hcv
EA201892507A1 (ru) Одноцепочечные редактирующие рнк олигонуклеотиды
LV14851A (lv) Triazolilpurīna atvasinājumi kā adenozīna un purīna receptoru agonisti

Legal Events

Date Code Title Description
FG Grant or registration